937.7500 -9.55 (-1.01%)
NSE Sep 09, 2025 15:31 PM
Volume: 73,236
 

Axis Direct
Q3 revenue beat (~8% above our estimate) was driven by strong growth in India (up 14% YoY) and US (up 9% YoY/24% QoQ in cc terms). EBITDA margin was up 360 bps YoY to 22.3% on better sales mix and lower R&D; spends.
Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.
More from Alembic Pharmaceuticals Ltd.
Recommended